small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (266)
  • Capabilities (77)
  • Experience (10)
  • Insights & News (2,215)
  • Other Results (109)

Professionals 266 results

Monica Lopez-Rodriguez
Monica Lopez-Rodriguez
Of Counsel
  • Miami
Email
+1 305-910-0501
vCard

Of Counsel

  • Miami
Yulia Makarova
Yulia Makarova
Partner of Winston & Strawn London LLP
  • London
Email
+44 20 7011 8803
vCard

Partner of Winston & Strawn London LLP

  • London
Alessandra Swanson
Alessandra Swanson
Partner
  • Chicago
Email
+1 312-558-7435
vCard

Partner

  • Chicago
View All Professionals

Capabilities 77 results

Practice Area

Financial Innovation & Regulation

Winston’s Financial Innovation & Regulation attorneys routinely counsel financial services, digital assets, and other clients on complex banking, crypto, FinTech, consumer financial, and securities matters. Many of our team members previously held positions as in-house counsel at global financial institutions and served in positions at government agencies, which gives us considerable experience in helping our clients obtain innovative, effective, and efficient solutions....Read more

Practice Area

Privacy: Regulated Personal Information (RPI)

Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond....Read more

Practice Area

Corporate Governance

Our attorneys have extensive experience counseling U.S. and multinational public companies across a range of industries in all aspects of corporate governance, securities, and compliance matters. We advise public companies, boards of directors and their committees, and senior executives on the corporate governance and compliance matters that public companies and their leadership confront—from board structuring and succession planning to shareholder activism and SEC regulation. Drawing on our experience as seasoned counselors, we keep clients abreast of evolving trends and best practices to proactively manage any governance or compliance issues. We have assembled one of the most experienced teams of any law firm in the country that’s counseling public companies....Read more

Experience 10 results

Experience

|

March 18, 2025

Winston Blunts Earnout Payment

Experience

|

February 10, 2025

US$600 million Total Play Telecomunicaciones S.A.P.I. de C.V. Offer to Exchange Senior Notes

Experience

|

May 10, 2024

Winston Establishes the Enforceability of Keepwell Bonds in Significant Hong Kong Court of Appeal Victory

Winston’s London Restructuring practice scores a significant win on appeal for Hong Kong and BVI liquidator claimants in the People’s Republic of China (PRC) based Peking University Founders Group Limited (PUFG) insolvency. ...Read more
View All Experience

Insights & News 2,215 results

Product Liability & Mass Torts Digest

|

August 22, 2025

|

5 Min Read

District Court Recognizes Loper Bright Does Not Undermine Basis for Express-Preemption Defense in Medical Device Cases

In what appears to be the first case to consider the issue, an Eastern District of Missouri court recently rejected the argument that the Supreme Court’s Loper Bright Enterprises v. Raimondo decision overruling Chevron deference undermines the basis for express preemption in medical device cases.

 

Webinar

|

August 21, 2025, 12:00 PM E.T.

The Current Debate about “Debanking”: Navigating Legal, Regulatory, and Reputational Challenges for Financial Institutions

Join our Financial Services Industry Group for a webinar focused on the key points in President Trump’s debanking executive order and recent debanking-related changes to the regulatory landscape. They will discuss expectations for debanking-related regulation and enforcement in the near future, as well as practical steps for financial institutions to manage associated risks and reduce the chances of becoming involved in debanking investigations. This webinar is part of a series covering the latest developments affecting our financial services clients. ...Read more

Tax Impacts

|

August 20, 2025

|

7 Min Read

Crypto Tax Update: New Tax Rules on the Horizon?

On July 30, President Trump’s Working Group on Digital Assets released its comprehensive “Strengthening American Leadership in Digital Financial Technology” report (the Report). The 160-plus-page report sets forth a series of recommendations seeking to “ensure crypto becomes a hallmark of the new American Golden Age” while outlining a proposed framework for regulating digital assets. A key section of the Report focuses on the taxation of digital assets and sets forth proposals on the modernization of the tax framework to better align with the realities of the digital asset ecosystem. The proposals address a range of substantive tax issues, including the classification of digital assets for tax purposes, the timing and character of income from mining and staking activities, and the tax treatment of stablecoins, and also recommends updates to taxpayer and third-party reporting requirements.

View All Insights & News

Other Results 109 results

Law Glossary

What Is the FDA?

The FDA stands for the Food and Drug Administration. It is a federal agency charged with protecting the public by regulating the safety and security of drugs, biological products, veterinary medications, and medical devices. FDA responsibilities also cover the safety of: foods for U.S. consumers, cosmetics, animal feed, and radiation-emitting products. Various rules may be established and enforced by the agency in response to U.S. laws or presidential executive orders....Read more

Law Glossary

What Is the Standard for the FDA to Grant a Biosimilar License?

Granting a Biosimilar License...Read more

Law Glossary

What Is the Standard for the FDA to Grant a Generic Drug License?

An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising